瘧疾疫苗的市場規模、佔有率、展望、機會 (2022年～2030年):各病原體、疫苗類型、流通管道、地區

Malaria Vaccines Market, by Agent, by Vaccine Type, by Distribution Channel and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: 2022年06月09日 | 出版商:

Coherent Market Insights | 英文 166 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

主要企業著重契約等成長策略的採用，預計促進在預測期間內的全球瘧疾疫苗市場成長。

本報告提供全球瘧疾疫苗的市場調查，市場定義和概要，市場成長的各種影響因素分析，法律制度，開發平台的分析，市場規模的變化、預測，各種區分、各地區/主要國家的明細，競爭環境，主要企業簡介等彙整資訊。

Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes. It is preventable and curable. Malaria vaccines are used to prevent the spread of malaria. The only approved vaccine, as of 2021, is RTS,S, known by the brand name Mosquirix. In October 2021, the World Health Organization (WHO) for the first time recommended the large-scale use of a malaria vaccine for children living in areas with moderate-to-high malaria transmission. Four injections of malaria vaccines are required for full protection.

Market Dynamics

Key players operating in the global malaria vaccine market are focusing on adoption of growth strategies such as agreements which are expected to drive market growth during the forecast period. For instance, in January 2021, GlaxoSmithKline (GSK), a science-led global healthcare company, PATH (Program for Appropriate Technology in Health), nonprofit global health organization based in Seattle, U.S., and Bharat Biotech (BBIL), is an Indian multinational biotechnology company announced the signing of a product transfer agreement for the malaria vaccine, RTS,S/AS01E. The agreement includes, transfer of manufacturing of the RTS,S antigen part of the vaccine and the grant of a license on all rights pertaining to the RTS,S/AS01 malaria vaccine to BBIL. GSK will retain the production of the adjuvant of the vaccine (AS01E) and will supply it to BBIL. Moreover, increasing research and development for malaria vaccine is expected to propel the global malaria vaccine market over the forecast period. For instance, in April 2021, scientists at the University of Oxford's Jenner Institute announced that their Phase IIb trial of a candidate malaria vaccine achieved 77% efficacy in early stage trials - making it the first malaria vaccine to meet the WHO's target of 75%. The Phase IIb trial of the vaccine candidate, R21, enrolled 450 children in Burkina Faso, one of the 10 countries with the highest cases of malaria and subsequent deaths.

Key features of the study:

This report provides in-depth analysis of the global malaria vaccine market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the Global Malaria vaccine Market based on the following parameters - Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
Key companies covered as a part of this study include GlaxoSmithKline, Nobelpharma, Sanaria, CellFree Sciences, VLP Therapeutics LLC, Sumaya Biotech, BioNTech, and Precigen, Inc
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The Global Malaria vaccine Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global malaria vaccine market.

Detailed Segmentation:

Global Malaria vaccine Market, By Agent :
- Plasmodium Falciparum
- Plasmodium Vivax
- Anopheles Species
Global Malaria vaccine Market, By Vaccine Type :
- Pre-Erythrocytic
- Erythrocytic
- Multi-antigen
Global Malaria vaccine Market, By Distribution Channel :
- Public
- Private
Global Malaria vaccine Market, By Region:
- North America
  - By Country
  - U.S.
  - Canada
- Latin America
  - By Country
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
- Europe
  - By Country
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
- Asia Pacific
  - By Country
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Middle East
  - By Country
  - GCC
  - Israel
  - Rest of Middle East
- Africa
  - By Country
  - South Africa
  - Central Africa
  - North Africa
Company Profiles
- GlaxoSmithKline.*
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Nobelpharma
- Sanaria
- CellFree Sciences
- VLP Therapeutics LLC
- Sumaya Biotech
- BioNTech
- Precigen, Inc

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Agent
- Market Snapshot, By Vaccine Type
- Market Snapshot, By Distribution Channels
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunity
Impact Analysis
Regulatory Scenario
Market Trends
Pipeline Analysis
Key Developments
Epidemiology
PEST Analysis
Collaboration and Acquisition
Porters Analysis
Vaccine Developmental Cycle

4. Global Malaria Vaccines Market - Impact of Coronavirus (COVID-19) Pandemic

Economic Impact
Impact on Demand and Supply
COVID-19 Impact Assessments

5. Global Malaria Vaccines Market, By Agent, 2017-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
Plasmodium Falciparum
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
Plasmodium Vivax
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
Anopheles Species
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)

6. Global Malaria Vaccines Market, By Vaccine Type, 2017-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
Pre-Erythrocytic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
Erythrocytic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
Multi-antigen
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)

7. Global Malaria Vaccines Market, By Distribution Channel, 2017-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
Public
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
Private
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)

8. Global Malaria Vaccines Market, By Region, 2017-2030, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Region, 2018-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Agent, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
- U.S.
- Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Agent, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Agent, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Agent, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Agent, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
- GCC
- Israel
- Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Agent, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017-2030,(US$ Mn)
- North Africa
- Central Africa
- South Africa

9. Competitive Landscape

Heat Map Analysis
Market Share Analysis
- GlaxoSmithKline
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Nobelpharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanaria
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- CellFree Sciences
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- VLP Therapeutics LLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sumaya Biotech
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- BioNTech
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Precigen, Inc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies